Stockreport

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

Taysha Gene Therapies, Inc.  (TSHA) 
PDF Completed dosing in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durab [Read more]